ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0974

Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers

Lucy Marie Carter1, Zoe Wigston1, Jack Arnold1 and Philip Laws2, 1University of Leeds, Leeds, United Kingdom, 2Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: ACR Convergence 2022

Keywords: Biologicals, Cutaneous, Dermatology, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype being particularly resistant. Local production and response to type-I interferon (IFN-I) is implicated in all subtypes of CLE and therapeutic blockade of the IFN-I receptor with anifrolumab has shown benefit on mucocutaneous SLE in clinical trials.

Response to anifrolumab in recalcitrant CLE and by specific lesion subtype have not yet been described. It is also unclear whether cutaneous responses are dependent upon direct effects on IFN-I signaling or subsequent downstream effects on other immune functions regulated by IFN-I. We hypothesise that the efficacy of anifrolumab will differ dependent on the relative contribution of direct IFN-I effects vs. the downstream immunostimulatory effects of IFN-I on other immune functions. Here we evaluate the effect of anifrolumab on (i) rituximab-refractory CLE; (ii) on DLE; (iii) to compare clinical responses with IFN-specific biomarkers and transcriptomic evaluation of broader immune responses; (iv) to compare early and late immunophenotypic and clinical responses.

Methods: SLE patients with active recalcitrant CLE received anifrolumab 300 mg IV every 4 weeks and evaluated using the Cutaneous lupus erythematosus disease area and severity index (CLASI) and dermatology life quality index (DLQI). Fluorescence intensity of tetherin (CD317), a cell surface interferon biomarker, was evaluated by multiparameter flow cytometry of peripheral blood mononuclear cells (PBMCs). Validated IFN-Scores, in addition to gene expression scores annotated to Inflammation, Myeloid lineage and Plasmablasts modules, were measured in PBMCs using customised Taqman array at serial time points.

Results: 7 patients (DLE n=5, chillblain / nodular vasculitis n= 1, subacute CLE n=1) have commenced therapy. Median number of previously failed standard therapies is 6, including rituximab in 6/7 patients, belimumab in 2/7 and thalidomide in 4/7. Three patients required long-term oral prednisolone >10 mg daily. Median baseline CLASI activity score was 17 and DLQI was 17/30.

Rapid clinical responses were evident at 1 month, with more rapid effects observed in patients with SCLE and DLE compared with chillblain lesions. Median fall in CLASI activity score at 1 month was 6 points with a median percentage change from baseline of 31%. All had achieved as ≥50% reduction in CLASI activity score by 3 months. In all patients, a rapid and marked suppression of IFN-Score-A (mean difference 2.92, p< 0.01) and plasmablast tetherin (p=0.01), was evident by 1 month. Small and variable downward trends were observed in Inflammation- and IFN-Score-B (p=0.06), Myeloid (p=0.27) and Plasmablast (p=0.15) -annotated gene expression scores.

Conclusion: These preliminary results suggest that anifrolumab: (i) may be effective in highly recalcitrant and rituximab-resistant CLE, (ii) is effective in DLE; (iii) rapidly suppresses IFN-I response, but with lesser effects on non-IFN immune biomarkers and (iv) early direct effects on IFN-I are associated with rapid clinical response.


Disclosures: L. Carter, None; Z. Wigston, None; J. Arnold, None; P. Laws, Amgen, Celgene, Eli Lilly, Sanofi, Janssen, AbbVie/Abbott, Bristol-Myers Squibb(BMS), UCB.

To cite this abstract in AMA style:

Carter L, Wigston Z, Arnold J, Laws P. Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rapid-efficacy-of-anifrolumab-across-multiple-subtypes-of-recalcitrant-cutaneous-lupus-erythematosus-parallels-discrete-changes-in-transcriptomic-and-cellular-biomarkers/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rapid-efficacy-of-anifrolumab-across-multiple-subtypes-of-recalcitrant-cutaneous-lupus-erythematosus-parallels-discrete-changes-in-transcriptomic-and-cellular-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology